It has previously been shown that ubiquitin-specific protease 2a (USP2a) is a regulator of the Mdm2/p53 pathway. USP2a binds to Mdm2 and can deubiquitinate Mdm2 without reversing Mdm2-mediated p53 ubiquitination. Overexpression of USP2a causes accumulation of Mdm2 and promotes p53 degradation. We now show that MdmX is also a substrate for USP2a. MdmX associates with USP2a independently of Mdm2. Ectopic expression of wild-type USP2a but not a catalytic mutant prevents Mdm2-mediated degradation of MdmX. This correlates with the ability of wild-type USP2a to deubiquitinate MdmX. siRNA-mediated knockdown of USP2a in NTERA-2 testicular embryonal carcinoma cells and MCF7 breast cancer cells causes destabilization of MdmX and results in a decrease in MdmX protein levels, showing that endogenous USP2a participates in the regulation of MdmX stability. The therapeutic drug, cisplatin decreases MdmX protein expression. USP2a mRNA and protein levels were also reduced after cisplatin exposure. The magnitude and time course of USP2a downregulation suggests that the reduction in USP2a levels could contribute to the decrease in MdmX expression following treatment with cisplatin. Knockdown of USP2a increases the sensitivity of NTERA-2 cells to cisplatin, raising the possibility that suppression of USP2a in combination with cisplatin may be an approach for cancer therapy.
Introduction
In response to multiple stresses including DNA damage, oncogene activation and hypoxia, the tumour-suppressor p53 is stabilized and its activity is increased leading to cell cycle arrest or apoptosis (Lane and Benchimol, 1990; Vousden and Lu, 2002) . p53 is repressed by Mdm2 and its homologue MdmX, which share high sequence similarity particularly in the p53-binding domain and the RING finger domains (Marine et al., 2007) . Mdm2 and MdmX are both essential negative regulators of p53 (Marine et al., 2006) . Mdm2 or MdmX null mice die during embryogenesis. In both cases this lethality can be rescued in a p53-null background (Montes de Oca Luna et al., 1995; Parant et al., 2001; Finch et al., 2002; Migliorini et al., 2002) . Targeting Mdm2 and/or MdmX is an approach to activate wild-type p53 for cancer therapy (Marine et al., 2007; Toledo and Wahl, 2007; Wade and Wahl, 2009 ). Suppression of Mdm2 causes cell cycle arrest and in some cases apoptosis in tumourderived cells expressing wild-type p53 (Vassilev, 2007) . Inhibiting MdmX can also have anti-tumour activity (Danovi et al., 2004; Gilkes et al., 2006) . However, targeting both Mdm2 and MdmX in cancer cells has been observed to have a greater pro-apoptotic effect than targeting either alone (Hu et al., 2006; Patton et al., 2006; Wade et al., 2006; Xia et al., 2008) .
Mdm2 can inhibit p53 activity by binding to its transactivation domain, and through promoting the proteasomal degradation of p53 by acting as an E3 ligase (Fang et al., 2000; Honda and Yasuda, 2000; Michael and Oren, 2003) . In mice, knockout of Mdm2 increases p53 protein levels and overall transactivation activity in both proliferating and post-mitotic cells. However, this occurs without an apparent increase in the specific activity of p53 Toledo et al., 2006) . This is consistent with a predominant role of Mdm2 in normal cells of promoting p53-degradation rather than transcriptional repression by direct binding to p53 (Itahana et al., 2007) . MdmX does not possess intrinsic ubiquitin E3 ligase activity towards p53 in vivo, but it binds to p53 and inhibits its transcriptional activity (Shvarts et al., 1996; Bottger et al., 1999) . However, there is evidence that Mdm2-MdmX heterodimers are involved in promoting the ubiquitination of p53 (Singh et al., 2007; Uldrijan et al., 2007; Linke et al., 2008) . It has also been suggested that MdmX may regulate the stability of p53 indirectly. Mdm2 and MdmX interact through their RING fingers and this interaction can stabilize Mdm2 and promote Mdm2-mediated degradation of p53 (Tanimura et al., 1999; Gu et al., 2002) . However, in mice MdmX knockout increases p53 transcriptional activity but has little or no effect on p53 levels (Marine et al., 2006) . In addition, no difference in the rate of Mdm2 degradation was observed in wild-type mouse embryonic fibroblasts and mouse embryonic fibroblasts derived from MdmX knockout mice, indicating that in at least some circumstances endogenous MdmX does not influence the half-life of Mdm2 Toledo et al., 2006) . These observations suggest that the predominant role of MdmX is to bind to p53 and repress its transcriptional activity; however, it is not clear to what extent the increased level of Mdm2 because of transcriptional activation of p53 can compensate for the loss of MdmX (Marine et al., 2006) .
MdmX is itself a substrate for the E3 ubiquitin ligase activity of Mdm2 (Kawai et al., 2003) . Mdm2 ubiquitinates MdmX and promotes its proteasomal degradation. Upon DNA damage MdmX is rapidly degraded via a Mdm2-dependent mechanism (Kawai et al., 2003) . In addition, DNA damage destabilizes Mdm2 by enhancing its proteasomal degradation (Stommel and Wahl, 2004) . The destabilization of these two repressors of p53 contributes to p53 activation (Wang et al., 2007) .
The deubiquitinating enzymes herpes virus-associated ubiquitin-specific protease (HAUSP)/USP7 and ubiquitin-specific protease 2a (USP2a) have been shown to regulate p53 by deubiquitinating components of the p53 pathway. In addition, p53 can be regulated more indirectly by the deubiquitinating enzyme USP5 (Dayal et al., 2009) . HAUSP can deubiquitinate p53, Mdm2 and MdmX and overexpression of HAUSP prevents p53 degradation. However, the balance of activity of endogenous HAUSP is such that its knockdown or knockout results in destabilization of Mdm2 and MdmX and stabilization of p53 (Li et al., 2002 (Li et al., , 2004 Cummins et al., 2004; Meulmeester et al., 2005) . We have previously shown that USP2a can deubiquitinate Mdm2 without reversing Mdm2-mediated p53 ubiquitination (Stevenson et al., 2007) . USP2a has oncogenic properties and its overexpression can prevent apoptosis induced by chemotherapeutic agents (Graner et al., 2004; Priolo et al., 2006) . USP2a knockdown results in increased p53 protein expression and upregulation of p53 target genes (Priolo et al., 2006; Stevenson et al., 2007) . USP2a mRNA is expressed in a range of normal tissues, the highest level of expression being in the testis (Lin et al., 2001; Park et al., 2002; Gousseva and Baker, 2003) . USP2a is overexpressed in prostate cancer (Graner et al., 2004) . This is associated with a reduction in p53 target gene expression, suggesting that USP2a overexpression could contribute to tumourigenesis by repression of p53 (Priolo et al., 2006) .
In this study, we show that MdmX is a substrate for USP2a. MdmX and USP2a form a complex in vitro and in vivo. Ectopically expressed USP2a deubiquitinates MdmX and prevents its Mdm2-mediated degradation. siRNA-mediated knockdown of USP2a enhances MdmX degradation, indicating that endogenous USP2a can regulate the stability of MdmX. In addition, we show that USP2a mRNA and protein levels are downregulated after cisplatin treatment and that knockdown of USP2a sensitizes cells to cisplatin.
Results

USP2a deubiquitinates MdmX
Ectopic expression of USP2a results in elevated levels of Mdm2 and an increase in degradation of p53 (Stevenson et al., 2007) . To determine the effect of USP2a on Mdm2-mediated degradation of MdmX, H1299 cells (p53 null) were co-transfected with plasmids expressing MdmX, Mdm2 and increasing amounts of plasmidexpressing USP2a. We examined the effects of HAUSP in parallel as it has previously been shown to prevent Mdm2-mediated degradation of MdmX (Meulmeester et al., 2005) . Mdm2 promoted MdmX degradation (Figure 1a , lane 3 compared with lane 2). Despite increasing Mdm2 protein levels, expression of USP2a (lanes 4-7), like expression of HAUSP (lanes 8-11), protected MdmX from Mdm2-mediated degradation. A His box catalytic mutant of USP2a (H549A) was not able to rescue MdmX from degradation indicating that this effect is dependent on the deubiquitinating activity of USP2a (Figure 1b, lane 3) . Overexpression of the deubiquitinating enzyme USP15 did not alter MdmX protein levels (Figure 1c , lanes 6-8) confirming that expression of a deubiquitinating enzyme per se does not protect MdmX from degradation.
To investigate whether MdmX is a substrate for USP2a we carried out an in vivo ubiquitination assay. 
USP2a forms a complex with MdmX
The ability of MdmX and USP2a to interact in vivo was determined by carrying out coimmunoprecipitation experiments. NTERA-2 testicular embryonal carcinoma cell lysates were incubated with anti-MdmX antibody or with rabbit IgG as a control. USP2a specifically coprecipitated with MdmX ( Figure 3a ). These data confirm that endogenous MdmX and USP2a can form a complex in vivo.
To further explore the interaction of MdmX and USP2a bacterially expressed GST or GST-MdmX were incubated with in vitro translated (IVT) USP2a. Fulllength USP2a (1-605) bound specifically to GSTMdmX ( Figure 3b , lane 7). This indicates that USP2a can associate with MdmX independently of Mdm2. To map MdmX-binding sites in USP2a we used a series of deletion constructs. Deletion of both the N and C-terminus of USP2a was required to abolish binding to MdmX (lane 12). These data indicate that there are at least two binding sites for MdmX in USP2a: one between amino acids 1-200 in its N-terminal extension and one between amino acids 403-503 in its catalytic core. Similarly, deletion of both the N and C-terminus of USP2a was required to prevent its binding to Mdm2 (Stevenson et al., 2007) .
To identify the region of MdmX involved in binding to USP2a, we incubated GST-MdmX deletion mutants with 35 S-labelled USP2a (Figure 3c ). USP2a bound to the C-terminal domain of MdmX (amino acids 393-490). These residues include the RING finger of MdmX (amino acids 437-483). The C-terminal domain of MdmX consistently pulled down less USP2a than the full-length protein. This could reflect the existence of an additional binding site in MdmX or it may be due to alterations in the conformation of the C-terminal domain when it is expressed outside the context of the full-length protein.
Mdm2 and MdmX hetero-oligomerize through their C-terminal RING finger domains (Tanimura et al., 1999) . To determine whether Mdm2 competes for binding of USP2a to MdmX, a GST pull down assay was carried out. Full-length GST-MdmX was incubated with increasing amounts of bacterially expressed Mdm2. Sufficient Mdm2 was added to saturate binding to MdmX (Figure 3d , lanes 9 and 10). Following incubation with Mdm2, the GST beads were washed and 35 S-labelled USP2a was added. Pre-incubation with Mdm2 did not block USP2a pull down by MdmX, suggesting that a trimeric complex can be formed between USP2a, Mdm2 and MdmX.
USP2a regulates the stability of MdmX in vivo To determine whether endogenous USP2a affects the levels of endogenous MdmX, NTERA-2 testicular Figure 2 USP2a deubiquitinates MdmX in vivo. H1299 cells were transfected where indicated with 2 mg of His 6 -ubiquitin, 6 mg of MdmX and 3 mg of Mdm2 expression vectors and 10 mg of constructs coding for wild-type USP2a and HAUSP or catalytic mutants of USP2a (H549A) and HAUSP (C223S). The cells were treated with 20 mM MG132 for 4 h before harvesting. His 6 -tagged ubiquitinated proteins were purified using Ni 2 þ -agarose beads and analysed by western blotting for MdmX (Ub-MdmX) and Mdm2 (Ub-Mdm2). Unmodified protein levels in cell lysates were analysed by direct western blot (lower four panels).
Regulation of MdmX by USP2a
N Allende-Vega et al embryonal carcinoma cells and MCF7 breast cancer cells were transfected with control siRNA or two siRNA complementary to different sequences in USP2a. The knockdown of USP2a was accompanied by a reduction in MdmX protein levels in both NTERA-2 ( Figure 4a ) and MCF7 cells (Supplementary Figure 1a) . USP2a siRNA also reduced Mdm2 protein levels and caused accumulation of endogenous wild-type p53 as observed previously (Stevenson et al., 2007) . To investigate whether the decrease in MdmX protein expression following USP2a knockdown was because of changes in its stability, NTERA-2 and MCF7 cells were transfected with control or USP2a siRNA and after 48 h cycloheximide was added to inhibit protein synthesis. 
USP2a is downregulated by cisplatin
Cisplatin treatment stabilizes p53, increases its transcriptional activity and causes apoptosis (Siddik, 2003) . It has been shown that some p53-activating stresses result in a decrease in the stability of MdmX and consequently a decrease in MdmX protein levels (Kawai et al., 2003; Gilkes et al., 2006) . To investigate whether changes in USP2a expression could be involved in regulation of MdmX following stress NTERA-2 cells were treated with 20 mM cisplatin for between 2 and 10 h as indicated (Figure 5a ). We observed an increase in p53 and Mdm2 protein expression whereas the levels of HAUSP remained constant. MdmX protein levels decreased significantly after cisplatin treatment. We also observed a decrease in USP2a protein levels. The kinetics of the decrease in USP2a protein expression are consistent with an involvement of decreased USP2a levels in destabilization of MdmX following treatment with cisplatin.
We next directly compared the effects of USP2a knockdown and cisplatin treatment alone and in combination. Cells were transfected with control siRNA or siRNA targeting USP2a. Forty-eight hours after transfection, the cells were incubated with 20 mM cisplatin for a further 8 h. At this time point no cell death was apparent. Cisplatin alone reduced USP2a protein levels by a comparable extent to transfection with siRNA targeting USP2a in both NTERA-2 cells (Figure 5b , lane 2 compared with lane 3) and in MCF7 cells (Supplementary Figure 2 , lane 3 compared with lane 2). In addition, we observed that USP2a mRNA levels were reduced after treatment with cisplatin ( Figure 5c ). The magnitude of the cisplatin-dependent decrease in USP2a mRNA levels was similar to that observed following transfection with USP2a siRNA. Little or no change in MdmX mRNA levels was observed consistent with the principle mechanism for its decreased expression following USP2a knockdown and DNA damage being destabilization of MdmX protein. These data suggest that USP2a downregulation resulting from a decrease in USP2a mRNA levels could contribute to the reduction in MdmX levels following DNA damage. (Figure 5c ) than either alone. USP2a knockdown resulted in lower Mdm2 and MdmX protein expression in both unstressed and cisplatin-treated cells. This is consistent with a role of USP2a in maintaining the stability of MdmX and Mdm2. mRNA levels of the p53 target genes Mdm2, p21 and Bax were increased to a greater extent by combined USP2a knockdown and cisplatin treatment than by either alone (Figure 5c ). This indicates that together they increase p53 transactivation activity to a greater extent. The effect of combined USP2a knockdown and incubation with cisplatin on cell viability was also investigated. Forty-eight hours after transfection, the cells were treated with the indicated concentration of cisplatin for a further 15 h (Figure 5d ). Cells transfected with the USP2a siRNA were sensitive to lower concentrations of cisplatin than the cells transfected with control siRNA. 
Regulation of MdmX by USP2a N Allende-Vega et al
Discussion
Mdm2 is deubiquitinated by USP2a and ectopic expression of USP2a causes accumulation of Mdm2 and promotes Mdm2-mediated p53 degradation (Stevenson et al., 2007) . Here, we show that MdmX is also a substrate for USP2a. In addition, we observed that USP2a mRNA and protein levels are decreased after cisplatin treatment. This could contribute to downregulation of MdmX following treatment with cisplatin.
MdmX and Mdm2 are two key repressors of p53. As well as promoting ubiquitination of p53, Mdm2 promotes the ubiquitination and proteasomal degradation of MdmX (Kawai et al., 2003) . In this study, we observed that ectopically expressed USP2a deubiquitinates MdmX and consequently inhibits Mdm2-mediated MdmX degradation. Endogenous USP2a and MdmX co-precipitate showing that they can form a complex when expressed at physiological levels. In NTERA-2 and MCF7 cells knockdown of endogenous USP2a causes a reduction in MdmX protein levels and stability. This is consistent with destabilization of MdmX as a result of reduced USP2a-mediated deubiquitination. USP2a binds to Mdm2 and is also required to maintain the stability of Mdm2 (Stevenson et al., 2007) . We observed that Mdm2 did not compete with USP2a for binding to MdmX. This indicates that USP2a can interact with MdmX in the presence of Mdm2, suggesting that a trimeric protein complex may be formed. USP2a could thus control the stability of the Mdm2/MdmX complex. The ability of USP2a to regulate the stability of both MdmX and Mdm2 provides a way to co-ordinately regulate these two repressors of p53. This is of relevance to the physiological regulation of p53 and makes USP2a an attractive potential target for p53-activating therapeutic agents. A greater effect on the viability of cancer-derived cells has been observed when both Mdm2 and MdmX are targeted. The importance of suppressing both Mdm2 and MdmX has been highlighted by studies involving nutlin. This compound disrupts the interaction between Mdm2 and p53 and consequently increases the transcriptional activity of p53 (Vassilev et al., 2004) . However, nutlin is not efficient at disrupting the interaction between MdmX and p53 (Hu et al., 2006; Wade et al., 2006) . In several studies it has been shown that MdmX can attenuate the effects of nutlin on cell viability, in particular on apoptosis (Hu et al., 2006; Patton et al., 2006; Wade et al., 2006; Barboza et al., 2008; Xia et al., 2008) .
Two regions of USP2a are involved in binding to MdmX. There are binding sites in the N-terminal extension (residues 1-200) and in the catalytic core of USP2a (residues 403-503). The presence of multiple MdmX-binding sites in USP2a could simply increase the overall strength of the interaction. In addition, it could allow binding of MdmX to USP2a in the correct orientation for deubiquitination or facilitate regulation of the catalytic activity of USP2a by MdmX. The crystal structure of the catalytic core of USP2 bound to ubiquitin has been determined (Renatus et al., 2006) . The structure of USPs bound to ubiquitin has been likened to a hand. The core of ubiquitin interacts with the fingers, palm and thumb of the USP2a hand, whereas the C-terminus of ubiquitin binds into a substrate cleft at the catalytic centre. Amino acids 403-503 do not include the active site Cys, QDE or Hisboxes but this region makes up four out of five of the 'fingers' which are involved in numerous contacts with the ubiquitin core (Renatus et al., 2006) .
Cisplatin is a p53-activating genotoxic drug widely used in the therapy of testicular and other cancers. We observed that cisplatin treatment resulted in a decrease in MdmX protein expression with little or no change in MdmX mRNA levels. Strikingly, USP2a was downregulated after cisplatin treatment. USP2a and MdmX downregulation occurred with similar kinetics. In addition, the magnitude of the cisplatin-induced decrease in USP2a expression was comparable with that observed following siRNA-mediated knockdown of USP2a. This decrease in USP2a protein levels is sufficient to cause destabilization of MdmX. These observations suggest that cisplatin-induced downregulation of USP2a could contribute to the decrease in MdmX levels in NTERA-2 cells resulting from treatment with the drug.
We observed that incubation with cisplatin resulted in a decrease in USP2a mRNA levels. This provides a mechanism for the cisplatin-induced decrease in USP2a protein expression. Cisplatin like other DNA-damaging drugs can inhibit transcription. Cisplatin binds covalently to DNA and forms intrastrand cross-links between neighbouring purine residues. This can cause stalling of RNA polymerase II at sites of damage and sequestration of factors required for transcription (Vichi et al., 1997; Cullinane et al., 1999; Siddik, 2003) . Under our experimental conditions cisplatin selectively reduced USP2a mRNA expression. Cisplatin did not change b-actin and TBP mRNA levels (data not shown) and it increased the mRNA expression of p53 target genes. Similarly, cisplatin was observed to selectively downregulate mRNA levels of the anti-apoptotic gene Bcl-X L (Campbell et al., 2006) . Cisplatin can have different effects on transcription from different promoters (Evans and Gralla, 1992) . Studies using gene expression arrays have also shown that only a subpopulation of mRNA is downregulated by cisplatin (Previati et al., 2004; Kruse et al., 2007) . The selectivity of the effect of cisplatin on USP2a mRNA levels could arise because transcription from the USP2a gene is particularly sensitive to cisplatin-DNA adducts or the mRNA of USP2a is unstable. The decrease in USP2a mRNA levels could be the result of the activation of DNA-damage-sensing pathways which for example regulate transcription or mRNA stability (Siddik, 2003) .
We show that USP2a suppression and cisplatin in combination induces greater activation of p53 than either alone and that USP2a knockdown sensitized cells to the effects of cisplatin on cell viability. USP2a knockdown in combination with cisplatin resulted in bigger increases in the mRNA levels of p53-responsive genes involved in both cell cycle arrest (p21) and apoptosis (Bax) than either alone. If cisplatin-dependent p53 activation were mediated by downregulation of USP2a then it would be anticipated that a combination of complete ablation of USP2a expression and cisplatin treatment would have a non-additive effect on the activity of p53. However, siRNA-mediated knockdown of USP2a only partially reduced its expression and cisplatin in combination with USP2a knockdown had a greater effect on USP2a mRNA and protein levels than either alone. Consistent with a requirement for USP2a in the stabilization of Mdm2 and MdmX, knockdown of USP2a resulted in lower protein levels of both Mdm2 and MdmX in cells treated with cisplatin. The lower levels of these two repressors of p53 could be responsible for the greater effect of cisplatin and USP2a knockdown in combination on the transcriptional activity of p53.
Non-genotoxic targeting of the negative regulators of p53 is a very attractive strategy for cancer therapy in tumours containing wild-type p53. This study shows that MdmX is a substrate for USP2a and indicates that through inhibition of USP2a a therapeutic agent could destabilize MdmX.
Materials and methods
Plasmids
Plasmids expressing human Mdm2, His 6 -ubiquitin, USP2a and HAUSP were described previously (Stevenson et al., 2007) . pcDNA3-MdmX (human) and pcDNA3-LacZ vectors were kindly provided by Dr AG Jochemsen.
Cell culture and transfection H1299 cells were cultured in RPMI medium supplemented with 10% FBS and penicillin/streptomycin at 37 1C and 5% CO 2 . For transfections 5 Â 10 5 cells were seeded per 10 cm dish and 2 h before transfection, the medium was replaced by DMEM, 10% FBS. Cells were transfected using the calcium-phosphate method with the indicated amounts of plasmids expressing human proteins and 2 mg of plasmid-expressing b-galactosidase (b-gal) as an internal control. Cells were washed with PBS and harvested 36 h post-transfection. Cell extracts were lysed into 2 Â SDS sample buffer and analysed by western blotting. NTERA-2 and MCF7 cell lines, which both express wild-type p53, were cultured in DMEM medium supplemented with 10% FBS and penicillin/streptomycin at 37 1C and in 10 and 5% CO 2 , respectively. For transfection with siRNA, NTERA-2 and MCF7 cells were plated at 1.5 Â 10 5 and 3 Â 10 5 cells/35 mm dish, respectively. Transfection with single siRNA synthetic duplexes (30 nM) was carried out using Oligofectamine (Invitrogen, Paisley, UK) according to the manufacturer's instructions. Nontargeting control duplex no. 2 was purchased from Dharmacon, Lafayette, CO, USA. The siRNA USP2a (1) is identical to that previously described (Priolo et al., 2006; Stevenson et al., 2007) and siRNA USP2a (2) targets the following sequence: CUCG UCCAUACUCCAAGAA.
Immunoprecipitation NTERA-2 cells were lysed in NP-40 buffer: 0.5% NP-40, 50 mM HEPES pH 7.5, 100 mM NaCl, 5 mM EDTA, 1 mM DTT and complete protease inhibitor mixture (Roche Applied Science, Burgess Hill, UK). Lysates matched for protein were incubated for 1 h with 2 mg of anti-MdmX (Bethyl Laboratories, Montgomery, TX, USA) or rabbit IgG at 4 1C. Protein G Sepharose beads were added and the lysate rocked for 1 h at 4 1C. The beads were washed three times with NP-40 buffer, eluted in 2 Â SDS sample buffer and analysed by western blotting.
Western blotting
The primary antibodies used were 4B2 for Mdm2; L523 for USP2a (Abgent, San Diego, CA, USA), BL1258 for MdmX (Bethyl Laboratories), HAUSP (USBiological, Swampscott, MA, USA) and anti-b-galactosidase monoclonal antibody (Calbiochem, Nottingham, UK) . An anti-USP2a polyclonal antibody was a gift from Dr S Wing. Cell extracts were lysed into 2 Â SDS sample buffer. Proteins were resolved by SDS-PAGE and transferred to nitrocellulose overnight at 25 mA. Peroxidase-coupled anti-mouse and anti-rabbit secondary antibodies were used at a dilution of 1:10 000 (Jackson Laboratories, West Grove, PA, USA). Bound antibodies were detected by enhanced chemiluminescence (Amersham, Little Chalfont, UK) or using Supersignal West Dura extended duration substrate (Pierce, Cramlington, UK).
In vivo ubiquitination assay
The ubiquitination assay relies on the transfection of cells with a plasmid coding His 6 -tagged ubiquitin followed by the capture and purification of ubiquitinated proteins from cell extracts using Ni 2 þ -agarose beads. This assay has been described in detail elsewhere (Xirodimas et al., 2001) . The purified ubiquitinated proteins were analysed by western blotting.
In vitro interaction assay 35 S-labelled USP2a was mixed with bacterially expressed GST or GST-MdmX for 2 h at 4 1C. This assay has been described in detail elsewhere (Stevenson et al., 2007) . Complexes were resolved by SDS-PAGE and bound 35 S-labelled protein detected by autoradiography.
Cell viability assay
Cell viability was measured according to the manufacturer's instructions using the CytoTox-ONE assay (Promega, Southampton, UK). Fluorescence was measured using a fluorescence spectrophotometer (Hitachi, Maidenhead, UK) at an excitation wavelength of 560 nm and an emission wavelength of 590 nm.
RNA preparation and real-time PCR Total RNA was extracted using RNeasy columns (Qiagen, Crawley, UK). RNA (300-600 ng) was incubated with random primers (Promega) and Superscript II reverse transcriptase (Invitrogen) to generate cDNA. Real-time PCR was carried out with an ABI Prism 7700 sequence detector using the following protocol: 50 1C for 2 min, 95 1C for 10 min and 40 cycles of 95 1C for 15 s and 60 1C for 1 min. p21, Bax, p53-responsive Mdm2-P2 transcript and MdmX primers and 6-FAM/TAMRA-labelled probes were used as described previously (Giglio et al., 2005; Stevenson et al., 2007) . USP2a primers and probes were as follows: 5 0 -CTCGTCCATCCTCCAAGAAGAG-3 0 , 5 0 -GAGG AGAGCTGGGACATCCTT-3 0 and probe 6-FAM-AGCCCAT GAGGCTCCCAGTCC-TAMRA.
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